Skip to main content
. 2016 Feb 23;11(5):803–811. doi: 10.2215/CJN.06300615

Figure 2.

Figure 2.

Effects of tolvaptan on the time to multiple investigator-assessed autosomal-dominant polycystic kidney disease (ADPKD)-related progression events hazard ratios for the key secondary endpoint of multiple investigator-assessed ADPKD-related progression events with tolvaptan compared with placebo by CKD stage. 95% CI, 95% confidence interval.